Gilead Sciences, Inc.
GILD
$96.96
-$1.20-1.22%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 6.67B | 7.57B | 7.55B | 6.95B | 6.69B |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 6.67B | 7.57B | 7.55B | 6.95B | 6.69B |
Cost of Revenue | 1.54B | 1.58B | 1.57B | 1.54B | 1.55B |
Gross Profit | 5.13B | 5.99B | 5.97B | 5.41B | 5.13B |
SG&A Expenses | 1.22B | 1.86B | 1.41B | 1.37B | 1.36B |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 4.10B | 5.07B | 4.38B | 4.26B | 4.38B |
Operating Income | 2.57B | 2.50B | 3.17B | 2.69B | 2.30B |
Income Before Tax | 1.65B | 2.17B | 956.00M | 2.05B | -4.49B |
Income Tax Expenses | 334.00M | 385.00M | -297.00M | 438.00M | -315.00M |
Earnings from Continuing Operations | 1.32B | 1.78B | 1.25B | 1.61B | -4.17B |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 1.32B | 1.78B | 1.25B | 1.61B | -4.17B |
EBIT | 2.57B | 2.50B | 3.17B | 2.69B | 2.30B |
EBITDA | 3.26B | 3.20B | 3.86B | 3.39B | 2.99B |
EPS Basic | 1.06 | 1.43 | 1.00 | 1.29 | -3.34 |
Normalized Basic EPS | 1.21 | 1.17 | 1.49 | 1.25 | 1.08 |
EPS Diluted | 1.04 | 1.41 | 1.00 | 1.29 | -3.34 |
Normalized Diluted EPS | 1.19 | 1.16 | 1.48 | 1.25 | 1.08 |
Average Basic Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B |
Average Diluted Shares Outstanding | 1.26B | 1.26B | 1.25B | 1.25B | 1.25B |
Dividend Per Share | 0.79 | 0.77 | 0.77 | 0.77 | 0.77 |
Payout Ratio | 76.81% | 54.57% | 78.45% | 60.22% | -23.74% |